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Abstract 
Background: 
Recent evidence supports that most non-lacunar cryptogenic strokes are embolic. 
Accordingly these strokes have been designated as embolic strokes of undetermined 
source (ESUS).  
Aims: 
We undertook an international survey to characterize the frequency and clinical features 
of ESUS patients across global regions. 
Methods: 
Consecutive patients hospitalized for ischemic stroke were retrospectively surveyed from 
19 stroke research centers in 19 different countries to collect patients meeting criteria for 
ESUS. 
Results:  
Of 2144 patients with recent ischemic stroke, 351 (16%, 95% CI 15% to 18%) met ESUS 
criteria, similar across global regions (range 16% to 21%), and an additional 308 (14%) 
patients had incomplete evaluation required for ESUS diagnosis. The mean age of ESUS 
patients (62 years; SD=15) was significantly lower than the 1793 non-ESUS ischemic 
stroke patients (68 years, p< 0.001). Excluding patients with atrial fibrillation (n = 590, 
mean age = 75 years), the mean age of the remaining 1203 non-ESUS ischemic stroke 
patients was 64 years (p=0.02 vs. ESUS patients). Among ESUS patients, hypertension, 
diabetes, and prior stroke were present in 64%, 25% and 17%, respectively. Median 
NIHSS score was 4 (interquartile range 2-8).  At discharge, 90% of ESUS patients 
received antiplatelet therapy and 7% received anticoagulation. 
Conclusions: 
This cross-sectional global sample of patients with recent ischemic stroke shows that one-
sixth met criteria for ESUS, with additional ESUS patients likely among those with 
incomplete diagnostic investigation. ESUS patients were relatively young with mild 
strokes. Antiplatelet therapy was the standard antithrombotic therapy for secondary stroke 
prevention in all global regions. 
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Introduction: 
Cryptogenic strokes are strokes of otherwise undetermined cause and comprise about 
25% all ischemic strokes.(1,2) There is evidence that most non-lacunar cryptogenic 
strokes are embolic based on an “open artery” supplying the area of brain infarction.(3) It 
has long been recognized that identification of the source of the embolus is often not 
possible, even at autopsy.(4,5)  Advances in diagnostic techniques have identified a 
substantial number of potential sources of embolism in patients with non-lacunar 
cryptogenic stroke.(1) Multiple potential embolic sources (e.g. a patent foramen ovale, 
left atrial stasis, aortic arch atherosclerosis) are often present in an individual patient, and 
identifying the culprit lesion cannot be done with certainty. This uncertainty has 
forestalled the development of randomized trials, and there has been little progress in 
secondary prevention of cryptogenic stroke in recent decades. 
 
Embolic strokes of undetermined source (ESUS) have in common thromboembolic 
mechanisms that may be more responsive to anticoagulants than antiplatelet therapy for 
secondary stroke prevention.(1) This is the basis for two large international randomized 
trials now ongoing that are comparing new selective oral anticoagulants with aspirin.(6,7) 
 
Relatively little is known about the frequency or clinical features of ESUS patients.(8) 
We undertook a global survey to determine the fraction of patients with acute ischemic 
stroke who meet criteria for ESUS and to characterize features of ESUS patients in 
different countries and across global regions. 
 
Methods: 
Consecutive patients with recent ischemic stroke were sought at 20 stroke research 
centers in 20 different countries, targeting review of 100 patients with acute ischemic 
stroke at each site or until 25 patients meeting ESUS criteria were identified. 
Investigators were selected based on participation on the Cryptogenic Stroke / ESUS 
International Working Group (1) and on regional distribution in countries involved in the 
NAVIGATE ESUS international randomized trial.(6) Sites were instructed to 
retrospectively identify consecutive inpatients evaluated for recent stroke in 2013- 2014 
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either from hospital discharge diagnosis codes or from databases associated with acute 
stroke units. Criteria for ESUS were those previously published.(Table 1)(1) A 9-page 
case report form was completed for each ESUS patient by a physician provided with 
specific instructions and definitions. The study was compliant with local institutional 
research board regulations; informed consent was not required at any site for this 
anonymized data collection based on medical record review.  
 
Data were analyzed according to five global regions: Europe, North America, Latin 
America, East Asia, and Pacific. Data from one site (Budapest, Hungary) were not 
included in the analyses because cardiac rhythm monitoring required for diagnosis of 
ESUS was not routinely carried-out (i.e. no patients met criteria for ESUS). Minor-risk 
cardioembolic sources were those previously described.(1) 
 
Case report forms were entered into a central database via on-line data entry or via an 
automated fax-based data entry system. Missing data were queried, and final data were 
exported to STATA 13.0 for statistical analysis. Descriptive analyses regarding the 
frequency of key features were done using T-test and Chi-square; and limited 
multivariate models were done to identify independent associations. 
 
Results: 
Frequency of ESUS by country and global region 
Of 2144 patients with recent ischemic stroke collected from 19 stroke research centers in 
19 countries, 351 (16%, 95%CI 15% to 18%) met ESUS criteria, ranging widely from 
1% in Amsterdam to 36% in Paris.(Table 2)  Of note, echocardiography (required for 
diagnosis) was not routinely carried-out in ischemic stroke patients in Amsterdam (done 
in 26% of ischemic stroke patients): excluding this site, the frequency of ESUS was 17%. 
Excluding 308 (14%) patients with incomplete evaluation required for ESUS 
diagnosis,(Figure) the frequency of ESUS was 19%.  
 
Among patients meeting criteria for ESUS, 40% underwent only 24-hour Holter 
monitoring, 33% had only >24 hours of inpatient cardiac telemetry, 19% had both 24-
 7 
hour Holter monitoring and inpatient cardiac telemetry, and 8% had either >24 hours of 
Holter monitoring or non-telemetry extended (>24 hours) of cardiac rhythm monitoring. 
 
Comparison of the frequency of ESUS according to global region was limited by small 
numbers of strokes and centers, but it was relatively uniform: 16% in all regions except 
East Asia (21%).(Table 3)  
 
Reasons that ischemic stroke patients did not meet ESUS criteria 
The most frequent reason that patients with ischemic stroke did not meet criteria for 
ESUS was identification of atrial fibrillation (n=590, 28% of all ischemic strokes). 
Additional reasons were visualized lacunar (small subcortical) infarcts (n=339, 16%), 
ipsilateral cervical carotid stenosis >50% (n=293, 14%), and absence of required 
visualization of index stroke on neuroimaging (n=115, 5%).(Figure)  In the remaining 
patients (n=308, 14%), insufficient evaluation was completed to assess the criteria 
required for ESUS diagnosis. For those with insufficient diagnostic testing to meet ESUS 
criteria, the mean age was 66 years, and 30-day mortality was 7%. 
 
Age and sex distribution of ESUS patients 
The mean ages of ESUS patients varied across sites: Beijing had the youngest mean age 
(48 years) and Brussels the oldest (74 years). Overall, the age of the 351 ESUS patients 
averaged 62 years (SD=15), but the mean age was younger (56 years) at the three East 
Asian sites vs. others (65 years)(p=0.002).(Table 4). The mean age of the ESUS patients 
was significantly lower than in the 1793 non-ESUS ischemic stroke patients (mean age 
68 years, p< 0.001). When patients with atrial fibrillation were excluded (n=590, mean 
age = 75 years), the mean age of the remaining 1204 non-ESUS ischemic stroke patients 
without atrial fibrillation was 64 years (p=0.02 vs. ESUS patients). Overall, 57% of 
ESUS patients were men, with sex distribution similar across global regions with the 
exception of 78% men at the three East Asian sites.(Table 4) 
 
Other clinical features of ESUS patients 
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Among the 351 ESUS patients, hypertension, diabetes, and coronary artery disease were 
present in 64%, 25%, and 10% respectively; 31% were taking antiplatelet therapy at 
stroke onset.(Table 4)  Seventeen percent of the ESUS patients had a history of stroke or 
TIA prior to the index stroke. Median (IQR) NIHSS score near hospital admission was 4 
(interquartile range 2-8); 16% received intravenous tPA at the time of the index stroke. 
MRIs were done in 77%, with an old ischemic stroke (i.e. prior to index stroke) present 
on MRI in 40%. Transesophageal echocardiography (TEE) was undertaken in 35% of 
ESUS patients, with complex aortic arch plaque reported in 6% of those undergoing 
TEE.(Table 4)  The 30-day mortality rate was 2% in ESUS patients compared with 10% 
in stroke patients with identified atrial fibrillation, and 5% in non-ESUS, non-atrial 
fibrillation patients. Contraindications to anticoagulant therapy were identified in 9%. At 
hospital discharge, 90% of ESUS patients received antiplatelet therapy, 7% anticoagulant 
therapy and 3% no antithrombotic therapy.(Table 4)  
 
Frequency of minor-risk potential embolic sources in ESUS patients 
Of ESUS patients with anterior circulation stroke, 79% had non-stenotic cervical carotid 
artery plaques with a mean diameter stenosis of 17%. Among those who underwent 
transthoracic (precordial) echocardiography, mitral annular calcification or myxomatous 
changes, aortic valve stenosis or calcification, and hypokinetic/ akinetic left ventricle 
were detected in 5%, 7%, and 4%, respectively.  Of the ESUS patients who underwent 
transesophageal echocardiography, aortic arch atherosclerotic plaques were present in 
29% and patent foremen ovale in 25%.  Seventy-four per cent of ESUS patients had at 
least one minor-risk potential embolic source identified, and 24% had two or more.(Table 
5) 
 
Discussion: 
This global survey found that ESUS patients comprise about one in six ischemic strokes 
at large international stroke centers (and likely higher at centers that routinely undertake 
the complete evaluation required to meet ESUS criteria). ESUS patients on average had 
relatively minor strokes with a low 30-day mortality rate (3%), and their mean age (62 
years) was similar to, but significantly lower than, that of non-ESUS stroke patients 
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without atrial fibrillation (64 years). The frequency and clinical features of ESUS patients 
were generally similar across global regions. Most (74%) ESUS patients had at least one 
minor-risk embolic source identified that could have been the cause of stroke, and nearly 
a quarter (24%) had two or more potential embolic sources identified.  Interestingly, the 
prevalence of patient foramen ovale among ESUS patients undergoing transesophageal 
echocardiography (25%) was not increased over that expected in the general population. 
 
Excluding patients who did not undergo the complete diagnostic investigation required 
for ESUS diagnosis (n=308, most often lack of intracranial arterial imaging), the 
frequency of ESUS was 19%. Considering an estimated 25% frequency of cryptogenic 
ischemic strokes based on the recent literature,(1) this frequency of ESUS supports the 
notion that most (but not all) non-lacunar cryptogenic ischemic strokes are likely due to 
embolism. 
 
The mild severity of stroke in ESUS patients is consistent with smaller emboli originating 
from cardiac valves and arterial sources, in contrast to larger emboli that typically 
originate in the cardiac chambers (e.g. left atrial thrombi in patients with atrial 
fibrillation.(9)  Our observations regarding stroke severity are consistent with those 
regarding ESUS patients from the Athens Stroke Registry.(8) The substantially younger 
age and milder strokes of ESUS patients compared with patients with atrial fibrillation-
associated stroke support different embolic origins (i.e. that undiagnosed paroxysmal 
atrial fibrillation is unlikely to underlie most ESUS). Alternatively, younger stroke patient 
may more often undergo the complete diagnostic evaluation required to meet ESUS 
criteria. Similarly, ischemic stroke patients with more severe strokes and/or early in-
hospital mortality may not have undergone all of the required diagnostic testing. 
 
Of interest, atrial fibrillation was identified in 28% of consecutive ischemic stroke 
patients, a higher fraction compared with hospitalized stroke patients in past decades 
(typically between 15-20%) probably due to both increasing vigilance and prevalence.  
Recent studies suggest that prolonged (>1 month) cardiac rhythm monitoring identifies 
additional patients with cryptogenic stroke who have episodes of paroxysmal atrial 
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fibrillation,(10,11) often very brief and of uncertain etiologic relevance.(12)  Small 
subcortical “lacunar” infarcts were visualized in 16% of ischemic stroke patients and 
excluded the diagnosis of ESUS; unidentified lacunar infarcts were likely over-
represented among the additional 5% of patients with non-visualization of strokes on 
neuroimaging.(Figure)  
 
Limitations of this study include participation by a limited number of selected, high-
volume stroke centers. A single site in each country may not accurately reflect the 
spectrum of stroke. However the study sites represented many global regions allowing 
characterization of ESUS patients around the world. To ensure data quality in this 
retrospective study, standardized data collection forms were used along with specific 
definitions. 
 
Antiplatelet therapy was used for secondary stroke prevention in 90% of ESUS patients, 
in-line with recent guideline recommendations.(13-15)  Although emboli vary in 
composition, almost all include, in whole or in part, thrombus, and it has been proposed 
that anticoagulants could offer more protection against recurrent stroke for ESUS patients 
than antiplatelet agents.(1) Contraindications to anticoagulation were identified in 
relatively  few (about 10%) ESUS patients. Currently, two large international randomized 
trials are underway comparing an oral factor Xa inhibitor and direct thrombin inhibitor, 
respectively, with aspirin for secondary prevention of stroke in ESUS patients, (6,7) as 
well as another phase II randomized trial.(16) 
 
In summary, this study provides a benchmark for the global frequency and clinical 
features of patients with ESUS. This contemporary cross-sectional sample shows 
generally consistent clinical features of the ESUS patients across global regions. ESUS 
patients comprise an important subset of ischemic stroke patients around the world: 16% 
fulfilled all diagnostic criteria for ESUS with additional ESUS patients likely among the 
14% with incomplete diagnostic investigation. The unresolved issue of anticoagulant vs. 
antiplatelet prophylaxis for optimal secondary prevention in ESUS is thus relevant to 
large numbers of stroke patients. 
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Figure legend: Frequency of embolic strokes of undetermined source (ESUS) as a 
proportion of all ischemic strokes. An unknown number of those with incomplete 
diagnostic testing were likely to be ESUS.
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Table 1. Diagnostic criteria for embolic stroke of undetermined source (ESUS)* 
1. Stroke visualized by CT or MRI that is not lacunar† 
2. Absence of extracranial or intracranial atherosclerosis causing ≥50% luminal stenosis 
or occlusion of arteries supplying the area of ischemia# 
3. No major-risk cardioembolic source of embolism^ by history, ECG, echocardiography 
and >24 hours of cardiac rhythm monitoring 
4. No other specific cause of ischemic stroke identified (e.g, arteritis, dissection, 
migraine/vasospasm, drug abuse) 
 
CT = computed tomography; MRI = magnetic resonance imaging; ECG = electrocardiogram. 
* Cryptogenic Stroke / ESUS International Working Group definition.(1) 
†Lacunar defined as a subcortical infarct <1.5 cm (≤2.0 cm on MRI diffusion images) in largest dimension. 
# Requires extracranial and intracranial arterial imaging using sonography, CT angiography or MR 
angiography of the relevant arteries. 
^Permanent or paroxysmal atrial fibrillation, sustained atrial flutter, intracardiac thrombus, mechanical 
prosthetic cardiac valve, atrial myxoma or other cardiac tumors, moderate/severe mitral stenosis, recent (<4 
weeks) myocardial infarction, valvular vegetations, or infective endocarditis. 
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Table 2: Frequency of ESUS patients by country 
 
City, Country Ischemic strokes  ESUS* 
n (%) N Mean age (years) 
 Buenos Aires, Argentina 73 68 24 (33%) 
 Perth, Australia 114 67 24 (21%) 
 Brussels, Belgium 119 74 17 (14%) 
 Sao Paulo, Brazil 86 60 15 (27%) 
 Hamilton, Canada 172 73 29 (17%) 
 Beijing, China 69 59 11 (16%) 
 Paris, France 69 69 25 (36%) 
 Heidelberg, Germany 91 73 18 (20%) 
 Galway, Ireland 140 71 10 (7%) 
 Rome, Italy 91 67 19 (21%) 
 Tokyo, Japan 75 68 18 (24%) 
 Mexico City, Mexico 225 56 21 (9%) 
 Amsterdam, Netherlands 99 68 1 (1%) 
 Manila, Philippines 175 62 23 (13%) 
 Coimbra, Portugal 123 74 23 (19%) 
 Moscow, Russia 106 66 24 (23%) 
 Seoul, Korea 124 69 26 (21%) 
 Glasgow, United Kingdom 73 67 5 (7%) 
 Philadelphia, United States 120 67 18 (15%) 
Total 2144 67 351 (16%) 
  
*ESUS = embolic stroke of undetermined source. See Table 1 for criteria. 
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Table 3. Frequency of ESUS patients by global region 
Region Ischemic strokes 
N 
ESUS patients* 
N (%) 
Europe (9 sites) 911 142 (16%) 
North America (2 sites) 292 47 (16%) 
Latin America (3 sites) 384 60 (16%) 
East Asia (3 sites) 268 55 (21%) 
Pacific^ (2 sites) 289 47 (16%) 
All regions 2144 351 (16%) 
*ESUS = embolic stroke of undetermined source. See Table 1 for criteria. 
^Australia and Philippines. 
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Table 4. Clinical features of ESUS patients overall and by global region* 
 All ESUS 
patients 
(n=351)  
ESUS patients by Global Region                                            
Europe 
(n=142) 
North America 
(n=47) 
Latin America 
(n=60) 
East Asia 
(n=55) 
Pacific 
(n=47) 
Mean age, yrs (SD) 62 (15) 65 (15) 63 (13) 59 (17) 56 (15) 61 (14) 
Men, % 57 60 51 42 78 51 
Diabetes mellitus, % 25 23 34 17 29 26 
Hypertension, % 64 63 89 56 56 63 
Coronary artery disease, % 10 11 15 5 0 28 
Current tobacco smoking, % 26 18 31 13 53 28 
Heart failure, % 2 4 0 0 0 0 
Peripheral vascular disease, % 3 4 34 5 0 0 
Antiplatelet therapy at index stroke, % 31 26 32 28 15 66 
Anticoagulant therapy at index stroke, % 1 2 0 2 0 2 
Estimated GFR <30 mL/min, % 1 0 0 0 5 0 
Clinical stroke or TIA prior to index stroke, % 17 15 17 20 15 22 
Old ischemic stroke on CT, % 32 31 44 35 29 17 
Old ischemic stroke on MRI, % 40 33 51 39 31 56 
Patent foramen ovale (precordial echo), % 6 6 0 15 4 9 
Transesophageal echocardiography (TEE)  
Patent foramen ovale by TEE, % 
Aortic arch plaque by TEE, % 
Complex/ulcerated aortic plaque by TEE, % 
 
25 
29 
6 
 
27 
37 
9 
 
25 
50 
13 
 
42 
15 
0 
 
17 
11 
0 
 
25 
25 
0 
i.v. tPA for index stroke, % 16 24 19 10 7 11 
Median NIH Stroke Scale score < 48 hours of 
stroke onset (IQR) 
4 (2,8) 5 (3,10) 6 (3,9) 4 (1,6) 2 (1,5) 4 (3,6) 
Modified Rankin Scale near discharge (SD) 2 (1) 2 (1) 2 (3) 2 (1) 1 (1) - 
Death within 30 days, % 2 3 4 0 0 4 
Any contraindication to anticoagulation, % 9 8 15 8 9 9 
Antiplatelet therapy at hospital discharge, % 90 92 87 90 93 85 
Anticoagulation at hospital discharge, % 6 4 13 8 7 4 
ESUS = embolic stroke of undetermined source; GRF = glomerular filtration rate; NIH = National 
Institutes of Health; tPA = tissue plasminogen activator, IQR = interquartile range. 
*Due to missing values, completeness of data ranges from 76% to 99% for the second column. 
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Table 5. Frequency of minor-risk embolic sources among ESUS patients 
 
Minor-risk potential embolic sources* N (%)  
Cervical carotid artery non-stenotic plaques** 208 (79%)  
Mitral valve disease: annular calcification and/or thickening 
with myxomatous changes# 
17 (5%)  
Aortic valve disease: stenosis and/or calcification# 24 (7%)  
Hypokinetic/ akinetic left ventricle# 13 (4%)  
Moderate-to-severely dilated left atrium# 19 (6%)  
Aortic arch atherosclerotic plaques^ 35 (28%)  
Patent foramen ovale# 19 (6%)  
Patent foramen ovale^ 31 (25%)  
Any minor-risk embolic source^^ 258 (74%)  
>2 minor-risk embolic sources 83 (24%)  
* Minor-risk embolic sources are those associated with a relatively low absolute rate of stroke such that they are often incidentally present 
when identified in a stroke patient rather than the stroke cause, and consequently have unclear management implications.(1) 
** Excluding those with posterior circulation ischemia. 
# Those who underwent transthoracic echocardiography 
^ Those who underwent transeosphageal echocardiography. 
^^ Excluding carotid artery plaques as a minor-risk source, the 35% (n=122) had one or more minor-risk sources.. 
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